Hormone replacement therapy and survival after colorectal cancer diagnosis.

Hormone replacement therapy and survival after colorectal cancer diagnosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hormone replacement therapy and survival after colorectal cancer diagnosis. Abstract Text:

Jennifer A Chan,Jeffrey A Meyerhardt,Andrew T Chan,Edward L Giovannucci,Graham A Colditz,Charles S Fuchs,

PURPOSE: Postmenopausal estrogen use has been shown to decrease the incidence of colorectal cancer, but there is limited information regarding the effect of estrogen use on survival after diagnosis of colorectal cancer. PARTICIPANTS AND METHODS: We examined the influence of postmenopausal estrogen use on mortality among 834 women participating in the Nurses' Health Study who were diagnosed with colorectal cancer between 1976 and 2000 and observed until death or June 2004, whichever came first. Colorectal cancer-specific mortality and overall mortality according to categories of hormone use were assessed. Cox proportional hazards models were used to calculate hazard ratios (HRs) adjusted for other risk factors for cancer survival. RESULTS: Postmenopausal estrogen use before diagnosis of colorectal cancer was associated with significant reduction in mortality. Compared with women with no prior estrogen use, those reporting current use before diagnosis had an adjusted HR of 0.64 (95% CI, 0.47 to 0.88) for colorectal cancer-specific mortality and 0.74 (95% CI, 0.56 to 0.97) for overall mortality. This inverse association between hormone use and mortality was most evident among women whose duration of use was less than 5 years. Longer durations and past use were not associated with significant survival benefit. Assessment of estrogen use after diagnosis demonstrated similar findings. CONCLUSION: Current postmenopausal estrogen use before diagnosis of colorectal cancer was associated with improved colorectal cancer-specific and overall mortality. This benefit was principally limited to women who initiated estrogens within 5 years of diagnosis. Additional efforts to understand mechanisms through which estrogens influence colorectal carcinogenesis and cancer progression seem warranted.

Hormone replacement therapy and survival after colorectal cancer diagnosis. Publishing Authors By Initials

JA Chan,JA Meyerhardt,AT Chan,EL Giovannucci,GA Colditz,CS Fuchs,

For similar investigative techniques: epidemiologic methods: statistics as topic: survival analysis research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: survival analysis research

PUBMED ID PMID:

MEDLINE DATE:

Hormone replacement therapy and survival after colorectal cancer diagnosis. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of clinical oncology : official journal of

VOLUME: 24

Page Numbers: 5680-6

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 20

MONTH: Dec

YEAR: 2006

Hormone replacement therapy and survival after colorectal cancer diagnosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Hormone replacement therapy and survival after colorectal cancer diagnosis. Keywords Mesh Terms:

KEYWORDS: Survival Analysis

MESH TERMS: mortality

Chemical & Substance for Abstract: Hormone replacement therapy and survival after colorectal cancer diagnosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Hormone replacement therapy and survival after colorectal cancer diagnosis.

AFFILIATION: Dana-Farber Cancer Institute, Dana 1220, Boston, MA 02115, USA. jang@partners.org

Country: United States

AGENCY: United States NCI

GRANT: T32 CA 09001

ACRONYM: CA

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hormone replacement therapy and survival after colorectal cancer diagnosis Related Publications

• 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
• Acute myelopathy. Retrospective clinical, laboratory, MRI and outcome analysis of 49 cases.
• Adjuvant and neoadjuvant approaches in gastric cancer.
• Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting.
• Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
• Calcium-pterin suppresses mitogen-induced tryptophan degradation and neopterin production in peripheral blood mononuclear cells.
• Canonical notch signaling functions as a commitment switch in the epidermal lineage.
• Cardiac tamponade: a life-threatening complication of Still's disease.
• Catenins: keeping cells from getting their signals crossed.
• Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts.
• Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer.
• Contribution of the frontal eye field to gaze shifts in the head-unrestrained monkey: effects of microstimulation.
• CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
• Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
• Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
• Focal adhesion kinase modulates tension signaling to control actin and focal adhesion dynamics.
• GABAA but not GABAB receptors in the rostral anterior cingulate cortex selectively modulate pain-induced escape/avoidance behavior.
• Hormone replacement therapy and survival after colorectal cancer diagnosis.
• Identification of novel genes in genomic islands that contribute to Salmonella typhimurium replication in macrophages.
• Long-term aspirin use and mortality in women.
• Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling.
• Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP.
• Neurogenesis in the adult brain: is there an association with mental disorders?
• Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells.
• Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
• Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts.
• Ruthenium-catalyzed mild C-H oxyfunctionalization of cyclic steroidal ethers.
• Suicide attempt aborted by an implantable defibrillator.
• Tcf3 governs stem cell features and represses cell fate determination in skin.
• The relationship between basal level of anxiety and the affective response to inflammation.